LSE:MGP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Medica Group Plc provides teleradiology reporting services to NHS trusts, private hospital groups, and diagnostic imaging companies in the United Kingdom. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Medica Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MGP is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MGP's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-4.0%

MGP

-0.8%

GB Healthcare

2.2%

GB Market


1 Year Return

-13.7%

MGP

-3.9%

GB Healthcare

-5.6%

GB Market

Return vs Industry: MGP underperformed the UK Healthcare industry which returned -4.7% over the past year.

Return vs Market: MGP underperformed the UK Market which returned -6.4% over the past year.


Shareholder returns

MGPIndustryMarket
7 Day-4.0%-0.8%2.2%
30 Day22.2%4.3%12.1%
90 Day-8.7%13.8%10.9%
1 Year-13.1%-13.7%-2.8%-3.9%-1.8%-5.6%
3 Year-41.9%-43.9%-25.8%-29.6%4.8%-7.9%
5 Yearn/a20.8%10.9%35.9%5.3%

Long-Term Price Volatility Vs. Market

How volatile is Medica Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medica Group undervalued compared to its fair value and its price relative to the market?

24.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MGP (£1.2) is trading below our estimate of fair value (£1.58)

Significantly Below Fair Value: MGP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MGP is good value based on its PE Ratio (27.5x) compared to the GB Healthcare industry average (27.8x).

PE vs Market: MGP is poor value based on its PE Ratio (27.5x) compared to the UK market (21.3x).


Price to Earnings Growth Ratio

PEG Ratio: MGP is poor value based on its PEG Ratio (1.3x)


Price to Book Ratio

PB vs Industry: MGP is overvalued based on its PB Ratio (3.6x) compared to the GB Healthcare industry average (1.5x).


Next Steps

Future Growth

How is Medica Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

20.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGP's forecast earnings growth (20.5% per year) is above the savings rate (1.2%).

Earnings vs Market: MGP's earnings (20.5% per year) are forecast to grow slower than the UK market (26.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MGP's revenue (13.6% per year) is forecast to grow faster than the UK market (6.6% per year).

High Growth Revenue: MGP's revenue (13.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MGP's Return on Equity is forecast to be low in 3 years time (17.7%).


Next Steps

Past Performance

How has Medica Group performed over the past 5 years?

26.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MGP has high quality earnings.

Growing Profit Margin: MGP's current net profit margins (11.7%) are lower than last year (18.2%).


Past Earnings Growth Analysis

Earnings Trend: MGP's earnings have grown significantly by 26.3% per year over the past 5 years.

Accelerating Growth: MGP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MGP had negative earnings growth (-37%) over the past year, making it difficult to compare to the Healthcare industry average (4.8%).


Return on Equity

High ROE: MGP's Return on Equity (13.2%) is considered low.


Next Steps

Financial Health

How is Medica Group's financial position?


Financial Position Analysis

Short Term Liabilities: MGP's short term assets (£26.2M) exceed its short term liabilities (£3.2M).

Long Term Liabilities: MGP's short term assets (£26.2M) exceed its long term liabilities (£13.3M).


Debt to Equity History and Analysis

Debt Level: MGP's debt to equity ratio (32%) is considered satisfactory.

Reducing Debt: MGP's debt to equity ratio has reduced from 1496.3% to 32% over the past 5 years.

Debt Coverage: MGP's debt is well covered by operating cash flow (98.6%).

Interest Coverage: MGP's interest payments on its debt are well covered by EBIT (28.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Medica Group current dividend yield, its reliability and sustainability?

1.42%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: MGP's dividend (1.42%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.68%).

High Dividend: MGP's dividend (1.42%) is low compared to the top 25% of dividend payers in the UK market (4.83%).


Stability and Growth of Payments

Stable Dividend: MGP has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: MGP's dividend payments have increased, but the company has only paid a dividend for 3 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (19.5%), MGP's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: MGP's dividends in 3 years are forecast to be well covered by earnings (29.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Stuart Quin

1.25yrs

Tenure

UK£381,169

Compensation

Dr. Stuart Quin, Ph.D., serves as Chief Executive Officer and Director of Medica Group Plc since September 1, 2019. Dr. Quin joins Medica from Synlab, where he was Head of Central and Eastern Europe, Middl...


CEO Compensation Analysis

Compensation vs Market: Stuart's total compensation ($USD514.19K) is about average for companies of similar size in the UK market ($USD616.36K).

Compensation vs Earnings: Insufficient data to compare Stuart's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Stuart Quin
CEO & Director1.25yrsUK£381.17k0.060%
£ 81.1k
Stephen Davies
Medical Director7.58yrsUK£232.00k1.49%
£ 2.0m
Richard Crispin Jones
CFO & Executive Director0.33yrno data0.016%
£ 22.1k
Sarah Burns
Chief Operating Officerno datano datano data
Marc O'Brien
Chief Information Officer0.92yrno data0.0093%
£ 12.5k
Julie West
Head of Governance & Complianceno datano datano data
David Evans
Head of Functional Architectno datano datano data
Gary Thompsett
Head of Service Deliveryno datano datano data
Ben Tromans
Head of Service Development & Deploymentsno datano datano data
Ian Edwards
Head of Information Security & Risk1.33yrsno datano data
Philip Bradley
Head of Reporter Liaison0.50yrno datano data
Suzanne Stevens
Head of Recruitment0.92yrno datano data

0.9yrs

Average Tenure

Experienced Management: MGP's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Stuart Quin
CEO & Director1.25yrsUK£381.17k0.060%
£ 81.1k
Stephen Davies
Medical Director7.58yrsUK£232.00k1.49%
£ 2.0m
Richard Crispin Jones
CFO & Executive Director0.33yrno data0.016%
£ 22.1k
Gordon Davies
Independent Chairmanno dataUK£100.00k0.10%
£ 135.6k
Stephen Whittern
Senior Independent Non-Executive Directorno dataUK£60.00k0.033%
£ 44.8k
Jo Easton
Independent Non-Executive Director1.67yrsUK£34.68k0.018%
£ 24.9k

1.5yrs

Average Tenure

58.5yo

Average Age

Experienced Board: MGP's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MGP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medica Group Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medica Group Plc
  • Ticker: MGP
  • Exchange: LSE
  • Founded: 2013
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: UK£134.648m
  • Shares outstanding: 111.28m
  • Website: https://www.medicagroup.co.uk

Number of Employees


Location

  • Medica Group Plc
  • One Priory Square
  • 6th Floor
  • Hastings
  • East Sussex
  • TN34 1EA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MGPLSE (London Stock Exchange)YesOrdinary SharesGBGBPMar 2017
MGPLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPMar 2017
2MIDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2017

Biography

Medica Group Plc provides teleradiology reporting services to NHS trusts, private hospital groups, and diagnostic imaging companies in the United Kingdom. It offers NightHawk emergency computerised tomogra...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/03 19:15
End of Day Share Price2020/12/03 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.